The maturation of antibody technology for the HIV epidemic

[1]  Chaim A. Schramm,et al.  Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies , 2014, Nature.

[2]  Saurabh Aggarwal,et al.  What's fueling the biotech engine—2012 to 2013 , 2014, Nature Biotechnology.

[3]  M. Nussenzweig,et al.  Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission , 2013, The Journal of experimental medicine.

[4]  Adam Godzik,et al.  bNAber: database of broadly neutralizing HIV antibodies , 2013, Nucleic Acids Res..

[5]  Michael S. Seaman,et al.  Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys , 2013, Nature.

[6]  M. Nussenzweig,et al.  Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia , 2013, Nature.

[7]  Paul J Conroy,et al.  A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications , 2013, Trends in Biotechnology.

[8]  L. Morris,et al.  Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes , 2013, PLoS pathogens.

[9]  Rolf Kaiser,et al.  HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice , 2013, Proceedings of the National Academy of Sciences.

[10]  S. Elledge,et al.  Autoreactivity and Exceptional CDR Plasticity (but Not Unusual Polyspecificity) Hinder Elicitation of the Anti-HIV Antibody 4E10 , 2013, PLoS pathogens.

[11]  Chaim A. Schramm,et al.  Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. , 2013, Immunity.

[12]  P. Hraber,et al.  Neutralizing IgG at the Portal of Infection Mediates Protection against Vaginal Simian/Human Immunodeficiency Virus Challenge , 2013, Journal of Virology.

[13]  Michael Hust,et al.  Expression of Recombinant Antibodies , 2013, Front. Immunol..

[14]  D. Ho,et al.  Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1 , 2013, Proceedings of the National Academy of Sciences.

[15]  J. Mascola,et al.  Heavy Chain-Only IgG2b Llama Antibody Effects Near-Pan HIV-1 Neutralization by Recognizing a CD4-Induced Epitope That Includes Elements of Coreceptor- and CD4-Binding Sites , 2013, Journal of Virology.

[16]  Diego Ellerman,et al.  Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies , 2013, Nature Biotechnology.

[17]  Serge Muyldermans,et al.  Nanobodies: natural single-domain antibodies. , 2013, Annual review of biochemistry.

[18]  P. Baeuerle,et al.  Targeting T cells to tumor cells using bispecific antibodies. , 2013, Current opinion in chemical biology.

[19]  E. Casanova,et al.  Exploration of BAC versus plasmid expression vectors in recombinant CHO cells , 2013, Applied Microbiology and Biotechnology.

[20]  Chaim A. Schramm,et al.  Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.

[21]  Andrew Burnette,et al.  Monoclonal antibody therapeutics with up to five specificities , 2013, mAbs.

[22]  W. Weissenhorn,et al.  A gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen Recognition , 2013, PLoS pathogens.

[23]  Ron Diskin,et al.  HIV therapy by a combination of broadly neutralizing antibodies in humanized mice , 2012, Nature.

[24]  I. Benhar,et al.  Selection of antibodies from synthetic antibody libraries. , 2012, Archives of biochemistry and biophysics.

[25]  J. Mascola,et al.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. , 2012, Immunity.

[26]  L. Sigal.  Basic science for the clinician 58: IgG subclasses. , 2012, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[27]  J. Bouchet,et al.  Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and co-receptor binding sites of HIV-1 gp120 , 2012, Retrovirology.

[28]  D. Burton,et al.  Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses , 2012, Science.

[29]  P A Marichal-Gallardo,et al.  State‐of‐the‐art in downstream processing of monoclonal antibodies: Process trends in design and validation , 2012, Biotechnology progress.

[30]  E. Rybicki,et al.  Plant made anti-HIV microbicides—A field of opportunity , 2012, Biotechnology Advances.

[31]  R. Weiss,et al.  Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization , 2012, The Journal of experimental medicine.

[32]  R. Center,et al.  Hyperimmune Bovine Colostrum as a Low-Cost, Large-Scale Source of Antibodies with Broad Neutralizing Activity for HIV-1 Envelope with Potential Use in Microbicides , 2012, Antimicrobial Agents and Chemotherapy.

[33]  Y. Michotte,et al.  Using microdialysis to analyse the passage of monovalent nanobodies through the blood–brain barrier , 2012, British journal of pharmacology.

[34]  R. Weiss,et al.  Llama antibody fragments have good potential for application as HIV type 1 topical microbicides. , 2012, AIDS research and human retroviruses.

[35]  Jerome H. Kim,et al.  Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys , 2011, Nature.

[36]  R. Kontermann,et al.  Strategies for extended serum half-life of protein therapeutics. , 2011, Current opinion in biotechnology.

[37]  David Baltimore,et al.  Antibody-based Protection Against HIV Infection by Vectored ImmunoProphylaxis , 2011, Nature.

[38]  P. T. N. Sarkis,et al.  Anti-gp120 Minibody Gene Transfer to Female Genital Epithelial Cells Protects against HIV-1 Virus Challenge In Vitro , 2011, PloS one.

[39]  J. Lai,et al.  Synthetic Fab fragments that bind the HIV-1 gp41 heptad repeat regions. , 2011, Biochemical and biophysical research communications.

[40]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[41]  Ron Diskin,et al.  Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.

[42]  J. Mullikin,et al.  Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing , 2011, Science.

[43]  Ron Milo,et al.  Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy , 2011, Nature.

[44]  T. Kepler,et al.  Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors , 2011, Journal of Virology.

[45]  Brigitte E. Sanders-Beer,et al.  Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus , 2011, Mucosal Immunology.

[46]  I. Wilson,et al.  Insect cells for antibody production: evaluation of an efficient alternative. , 2011, Journal of biotechnology.

[47]  U. Brinkmann,et al.  Development of Tetravalent, Bispecific CCR5 Antibodies with Antiviral Activity against CCR5 Monoclonal Antibody-Resistant HIV-1 Strains , 2011, Antimicrobial Agents and Chemotherapy.

[48]  S. Zolla-Pazner,et al.  Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies , 2010, Nature Structural &Molecular Biology.

[49]  Maxim N. Artyomov,et al.  Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation , 2010, Nature.

[50]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[51]  C. Fichtenbaum,et al.  Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults , 2010, Antimicrobial Agents and Chemotherapy.

[52]  Yusen Zhou,et al.  A novel trifunctional IgG-like bispecific antibody to inhibit HIV-1 infection and enhance lysis of HIV by targeting activation of complement , 2010, Virology Journal.

[53]  I. Correia,et al.  Stability of IgG isotypes in serum , 2010, mAbs.

[54]  H. Liao,et al.  Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance , 2009, Proceedings of the National Academy of Sciences.

[55]  D. Burton,et al.  Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10 Directed against the Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Protect against Mucosal Challenge by Simian-Human Immunodeficiency Virus SHIVBa-L , 2009, Journal of Virology.

[56]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[57]  A. Rivkin.  Certolizumab pegol for the management of Crohn's disease in adults. , 2009, Clinical therapeutics.

[58]  Philip R. Johnson,et al.  Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys , 2009, Nature Medicine.

[59]  S. Nishimura,et al.  Crucial Role of Aspartic Acid at Position 265 in the CH2 Domain for Murine IgG2a and IgG2b Fc-Associated Effector Functions1 , 2008, The Journal of Immunology.

[60]  R. Weiss,et al.  Llama Antibody Fragments with Cross-Subtype Human Immunodeficiency Virus Type 1 (HIV-1)-Neutralizing Properties and High Affinity for HIV-1 gp120 , 2008, Journal of Virology.

[61]  S. Ayres,et al.  Induction of HIV-1 MPR(649-684)-specific IgA and IgG antibodies in caprine colostrum using a peptide-based vaccine. , 2008, Vaccine.

[62]  D. Rayson,et al.  The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada , 2008, Current oncology.

[63]  L. Cavacini,et al.  A Bispecific Antibody Composed of a Nonneutralizing Antibody to the gp41 Immunodominant Region and an Anti-CD89 Antibody Directs Broad Human Immunodeficiency Virus Destruction by Neutrophils , 2008, Journal of Virology.

[64]  Sahana Bose,et al.  Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin , 2007, Nature Biotechnology.

[65]  D. Burton,et al.  Fc receptor but not complement binding is important in antibody protection against HIV , 2007, Nature.

[66]  A. Nadkarni,et al.  Optimization of a mouse recombinant antibody fragment for efficient production from Escherichia coli. , 2007, Protein expression and purification.

[67]  S. Bregenholt,et al.  Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infections. , 2006, Current pharmaceutical design.

[68]  R. Markham,et al.  Lactobacilli-Expressed Single-Chain Variable Fragment (scFv) Specific for Intercellular Adhesion Molecule 1 (ICAM-1) Blocks Cell-Associated HIV-1 Transmission across a Cervical Epithelial Monolayer1 , 2006, The Journal of Immunology.

[69]  P. Kufer,et al.  BiTEs: bispecific antibody constructs with unique anti-tumor activity. , 2005, Drug discovery today.

[70]  Peter Kirkpatrick.  Medicinal chemistry: Best of both worlds? , 2005, Nature Reviews Drug Discovery.

[71]  Byung-Kwon Choi,et al.  Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[72]  D. Richman,et al.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[73]  John P. Moore,et al.  Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120 , 2003, Nature Medicine.

[74]  H. Katinger,et al.  Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques , 2003, AIDS.

[75]  R. Rau.  Adalimumab (a fully human anti-tumour necrosis factor α monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials , 2002, Annals of the rheumatic diseases.

[76]  H. Katinger,et al.  A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1 , 2002, AIDS.

[77]  C. Cheng‐Mayer,et al.  Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro , 2001, Journal of Virology.

[78]  H. Brühl,et al.  Depletion of CCR5-Expressing Cells with Bispecific Antibodies and Chemokine Toxins: A New Strategy in the Treatment of Chronic Inflammatory Diseases and HIV , 2001, The Journal of Immunology.

[79]  R. Pomerantz,et al.  Technology evaluation: PRO-542, Progenics Pharmaceuticals inc. , 2000, Current opinion in molecular therapeutics.

[80]  J. Mascola,et al.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.

[81]  Tahir A. Rizvi,et al.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.

[82]  J. Mascola,et al.  Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.

[83]  N. Haigwood,et al.  Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys , 1999, Nature Medicine.

[84]  M. Goldenberg.  Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. , 1999, Clinical therapeutics.

[85]  A. Plückthun,et al.  Antibody scFv fragments without disulfide bonds made by molecular evolution. , 1998, Journal of molecular biology.

[86]  J. Mascola,et al.  Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12 , 1997, Journal of virology.

[87]  D R Burton,et al.  Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. , 1997, AIDS research and human retroviruses.

[88]  E A Emini,et al.  Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. , 1997, AIDS research and human retroviruses.

[89]  A. Pinter,et al.  Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site , 1996, Journal of virology.

[90]  D R Burton,et al.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.

[91]  S. Marsters,et al.  A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells. , 1994, Journal of hematotherapy.

[92]  D R Burton,et al.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.

[93]  D. Dormont,et al.  Antibody-dependent cellular cytotoxicity and neutralization of human immunodeficiency virus type 1 by high affinity cross-linking of gp41 to human macrophage Fc IgG receptor using bispecific antibody. , 1994, The Journal of general virology.

[94]  A. Tramontano,et al.  The making of the minibody: An engineered β‐protein for the display of conformationally constrained peptides , 1994, Journal of molecular recognition : JMR.

[95]  M. Fanger,et al.  Targeting HIV‐1 to FcγR on human phagocytes via bispecific antibodies reduces infectivity of HIV‐1 to T cells , 1994, Journal of leukocyte biology.

[96]  J. Greenwood,et al.  Structural motifs involved in human IgG antibody effector functions , 1993, European journal of immunology.

[97]  A. Lanzavecchia,et al.  Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells. , 1991, The EMBO journal.

[98]  K. Steimer,et al.  Bispecific antibodies that mediate killing of cells infected with human immunodeficiency virus of any strain. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[99]  K. D. Hardman,et al.  Single-chain antigen-binding proteins. , 1988, Science.

[100]  R. Bruccoleri,et al.  Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[101]  R. R. Robinson,et al.  Escherichia coli secretion of an active chimeric antibody fragment. , 1988, Science.

[102]  Lutz Riechmann,et al.  Reshaping human antibodies for therapy , 1988, Nature.

[103]  S. Kent,et al.  The high cost of fidelity. , 2014, AIDS research and human retroviruses.